DIVISLAB

DIVI'S LABORATORIES

Large Cap BSE: 532488 NSE: DIVISLAB
₹3726.2
-221.85 (-5.62%)
  • Advice
  • Hold
As on 13 August, 2022 | 23:31

Divi's Laboratories Share Price

Divi's Laboratories Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Divi's Laboratories Share Returns

  • Over 1 Month 1.05%
  • Over 3 Month -11.98%
  • Over 6 Month -13.17%
  • Over 1 Year -24.09%

Divi's Laboratories Key Statistics

P/E Ratio 31.9
PEG Ratio 0.6
Market Cap Cr 98,919
Price to Book Ratio 8.4
EPS 111.1
Dividend 1.3
Relative Strength Index 43.91
Money Flow Index 47.27
MACD Signal 45.66
Average True Range 88.93

Divi's Laboratories Investment Rating

  • Master Rating:
  • Divis Laboratories (Nse) has an operating revenue of Rs. 9,253.71 Cr. on a trailing 12-month basis. An annual revenue growth of 29% is outstanding, Pre-tax margin of 41% is great, ROE of 25% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 200DMA and close to its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 98 which is a GREAT score indicating consistency in earnings, a RS Rating of 15 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 97 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Divi's Laboratories Financials
  • Indicator
  • Jun 2022
  • Mar 2022
  • Dec 2021
  • Sep 2021
  • Jun 2021
  • Mar 2021
  • Oper Rev Qtr Cr
  • 2,204
  • 2,495
  • 2,467
  • 1,968
  • 1,950
  • 1,718
  • Operating Expenses Qtr Cr
  • 1,366
  • 1,399
  • 1,367
  • 1,149
  • 1,099
  • 1,019
  • Operating Profit Qtr Cr
  • 838
  • 1,096
  • 1,100
  • 819
  • 851
  • 699
  • Depreciation Qtr Cr
  • 83
  • 81
  • 80
  • 77
  • 73
  • 70
  • Interest Qtr Cr
  • 0
  • 0
  • 0
  • 0
  • 0
  • 0
  • Tax Qtr Cr
  • 152
  • 183
  • 129
  • 154
  • 262
  • 164
  • Net Profit Qtr Cr
  • 692
  • 883
  • 907
  • 606
  • 552
  • 488

Divi's Laboratories Technicals

EMA & SMA

Current Price
3726.2
-221.85 (-5.62%)
  • Bullish Moving Average
  • ___
  • 1
  • Bearish Moving Average
  • ___
  • 15
  • 20 Day
  • 3818.15
  • 50 Day
  • 3804.82
  • 100 Day
  • 3938.7
  • 200 Day
  • 4251.99
  • 20 Day
  • 3814.17
  • 50 Day
  • 3685.9
  • 100 Day
  • 3976.58
  • 200 Day
  • 4250.93

Divi's Laboratories Resistance and Support

PIVOT
₹3936.05
Resistance
  • First Resistance
  • 3967.05
  • Second Resistance
  • 3986.05
  • Third Resistance
  • 4017.05
Support
  • First Resistance
  • 3917.05
  • Second Resistance
  • 3886.05
  • Third Resistance
  • 3867.05
  • RSI
  • 43.91
  • MFI
  • 47.27
  • MACD Single Line
  • 45.66
  • MACD
  • 45.13

Divi's Laboratories Delivery and Volume

  • Period
  • NSE + BSE
    Volume Avg
  • NSE + BSE
    Delivery Volume Avg
  • NSE + BSE
    Delivery Volume %
  • Day
  • 2,239,149
  • 81,885,679
  • 36.57
  • Week
  • 784,110
  • 32,242,613
  • 41.12
  • 1 Month
  • 422,149
  • 18,591,459
  • 44.04
  • 6 Month
  • 537,480
  • 24,369,321
  • 45.34

Divi's Laboratories Result Highlights

Divi's Laboratories Synopsis

NSE-Medical-Generic Drugs

Divi's Lab is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 8879.82 Cr. and Equity Capital is Rs. 53.09 Cr. for the Year ended 31/03/2022. Divi's Laboratories Ltd. is a Public Limited Listed company incorporated on 12/10/1990 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1990PLC011854 and registration number is 011854.
  • Market Cap
  • 98,919
  • Sales
  • 9,134
  • Shares in Float
  • 12.74
  • No of funds
  • 791
  • Yield
  • 0.81
  • Book Value
  • 8.46
  • U/D Vol ratio
  • 1.1
  • LTDebt / Equity
  • Alpha
  • -0.13
  • Beta
  • 0.84

Divi's Laboratories

  • Owner Name
  • Jun-22
  • Mar-22
  • Dec-21
  • Sep-21
  • Promoters
  • 51.94%
  • 51.94%
  • 51.95%
  • Mutual Funds
  • 13.85%
  • 13.68%
  • 13.35%
  • Foreign Portfolio Investors
  • 16.52%
  • 18.45%
  • 19.3%
  • Financial Institutions/ Banks
  • 0.09%
  • 0.05%
  • 0.05%
  • Individual Investors
  • 9.53%
  • 9.27%
  • 9.01%
  • Others
  • 8.07%
  • 6.61%
  • 6.34%

Divi's Laboratories Management

  • Name
  • Designation
  • Dr. Ramesh B V Nimmagadda
  • Non Exe.Chairman&Ind.Director
  • Dr. Murali K Divi
  • Managing Director
  • Dr. Kiran S Divi
  • WholeTime Director & CEO
  • Ms. Nilima Prasad Divi
  • Whole Time Director
  • Mr. Madhusudana Rao Divi
  • Whole Time Director
  • Mr. N V Ramana
  • Executive Director
  • Mr. K V K Seshavataram
  • Independent Director
  • Dr. G Suresh Kumar
  • Independent Director
  • Mr. R Ranga Rao
  • Independent Director
  • Prof. Sunaina Singh
  • Independent Director
  • Dr. S Ganapaty
  • Independent Director
  • Mr. K V Chowdary
  • Independent Director

Divi's Laboratories Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Divi's Laboratories Corporate Action

  • Date
  • Purpose
  • Remarks
  • 2022-08-12
  • Quarterly Results
  • 2022-05-23
  • Audited Results & Dividend
  • 2022-02-11
  • Quarterly Results
  • (Revised) per share(500%)Dividend
  • 2021-11-06
  • Quarterly Results
  • 2021-08-07
  • Quarterly Results
  • Date
  • Purpose
  • Remarks
  • 2022-08-12
  • FINAL
  • Rs.30.00 per share(1500%)Dividend

Divi's Laboratories MF Shareholding

  • Name
  • Amount(cr)
  • SBI Nifty 50 ETF
  • 135323
  • SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl
  • 53018
  • ICICI Prudential Balanced Advantage Fund Growth
  • 41742
  • Axis Bluechip Fund Growth
  • 35915
  • UTI Nifty 50 Exchange Traded Fund
  • 33453

Divi's Laboratories FAQs

What is Share Price of Divi's Laboratories ?

Divi's Laboratories share price is ₹3726 As on 13 August, 2022 | 23:17

What is the Market Cap of Divi's Laboratories ?

The Market Cap of Divi's Laboratories is ₹98918.9 Cr As on 13 August, 2022 | 23:17

What is the P/E ratio of Divi's Laboratories ?

The P/E ratio of Divi's Laboratories is 31.9 As on 13 August, 2022 | 23:17

What is the PB ratio of Divi's Laboratories ?

The PB ratio of Divi's Laboratories is 8.4 As on 13 August, 2022 | 23:17

What does Divis Laboratories do?

Divis Laboratories Ltd is an active pharmaceutical ingredient (API) and intermediates company situated in India. Divis Laboratories specialises in the production of leading generic chemicals, nutraceutical components, and custom API and intermediate synthesis for worldwide innovators.

Is Divis Laboratories good for the long term?

Divis Laboratories has an operating revenue of INR 7,437.78 Cr. on a trailing 12-month basis. Annual revenue growth of 26% is outstanding, Pre-tax margin of 38% is great, ROE of 21% is exceptional. Institutional holding in Divis Laboratories has gone up in the last reported quarter is a positive sign. As per analysts rating in the last 6 months, the recommendation is to HOLD Divis Laboratories.

Is Divis Laboratories debt-free?

Divis Laboratories is debt-free and has a strong balance sheet enabling it to report stable earnings growth across business cycles.

Who is the owner of Divis Laboratories?

Murali Divi is the founder of Divis Laboratories, one of the top three manufacturers of active pharmaceutical ingredients (API).

Q1FY23